Amicus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Amicus Therapeutics has been growing earnings at an average annual rate of 18%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 17.4% per year.
Key information
18.0%
Earnings growth rate
22.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.4% |
| Return on equity | -58.5% |
| Net Margin | -21.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Revenue & Expenses Breakdown
How Amicus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 494 | -105 | 307 | 114 |
| 30 Jun 24 | 456 | -120 | 297 | 129 |
| 31 Mar 24 | 423 | -147 | 289 | 139 |
| 31 Dec 23 | 399 | -152 | 275 | 152 |
| 30 Sep 23 | 372 | -174 | 259 | 181 |
| 30 Jun 23 | 351 | -185 | 241 | 193 |
| 31 Mar 23 | 337 | -204 | 229 | 237 |
| 31 Dec 22 | 329 | -237 | 213 | 277 |
| 30 Sep 22 | 323 | -264 | 216 | 298 |
| 30 Jun 22 | 321 | -281 | 215 | 305 |
| 31 Mar 22 | 318 | -270 | 204 | 289 |
| 31 Dec 21 | 306 | -250 | 193 | 272 |
| 30 Sep 21 | 294 | -239 | 179 | 266 |
| 30 Jun 21 | 282 | -252 | 171 | 277 |
| 31 Mar 21 | 267 | -254 | 163 | 283 |
| 31 Dec 20 | 261 | -277 | 156 | 308 |
| 30 Sep 20 | 246 | -295 | 156 | 321 |
| 30 Jun 20 | 227 | -293 | 158 | 310 |
| 31 Mar 20 | 209 | -325 | 166 | 311 |
| 31 Dec 19 | 182 | -356 | 170 | 286 |
| 30 Sep 19 | 160 | -345 | 272 | 145 |
| 30 Jun 19 | 131 | -442 | 265 | 224 |
| 31 Mar 19 | 109 | -419 | 251 | 188 |
| 31 Dec 18 | 91 | -349 | 127 | 271 |
| 30 Sep 18 | 73 | -340 | 117 | 251 |
| 30 Jun 18 | 64 | -293 | 106 | 154 |
| 31 Mar 18 | 49 | -279 | 97 | 151 |
| 31 Dec 17 | 37 | -284 | 88 | 141 |
| 30 Sep 17 | 25 | -273 | 82 | 137 |
| 30 Jun 17 | 16 | -208 | 78 | 122 |
| 31 Mar 17 | 9 | -211 | 78 | 109 |
| 31 Dec 16 | 5 | -200 | 71 | 105 |
| 30 Sep 16 | 2 | -184 | 72 | 88 |
| 30 Jun 16 | 0 | -175 | 70 | 100 |
| 31 Mar 16 | 0 | -152 | 59 | 90 |
| 31 Dec 15 | 0 | -132 | 50 | 74 |
| 30 Sep 15 | 0 | -110 | 36 | 62 |
| 30 Jun 15 | 0 | -90 | 25 | 30 |
| 31 Mar 15 | 1 | -77 | 22 | 27 |
| 31 Dec 14 | 1 | -69 | 23 | 45 |
| 30 Sep 14 | 2 | -60 | 19 | 24 |
| 30 Jun 14 | 1 | -57 | 19 | 24 |
| 31 Mar 14 | 1 | -58 | 19 | 26 |
| 31 Dec 13 | 0 | -60 | 19 | 28 |
Quality Earnings: FOLD is currently unprofitable.
Growing Profit Margin: FOLD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FOLD is unprofitable, but has reduced losses over the past 5 years at a rate of 18% per year.
Accelerating Growth: Unable to compare FOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: FOLD has a negative Return on Equity (-58.54%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amicus Therapeutics, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Michael Ulz | Baird |
| Yun Zhong | Berenberg |